Trevi Therapeutics, Inc.

NASDAQ•TRVI

CEO: Ms. Jennifer L. Good

板块: Healthcare

行业: Biotechnology

上市日期: 2019-05-07

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER (CORAL) clinical trial for treatment of chronic cough in patients with IPF; phase 2a Refractory Chronic Cough Improvement Via NAL ER (RIVER) clinical trial for reducing chronic cough in RCC patients; phase 2 clinical trial in patients with pruritus; phase 2b/3 clinical trial in patients with prurigo nodularis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.

联系方式

195 Church Street, 16th Floor, New Haven, CT, 06510, United States

203-304-2499

www.trevitherapeutics.com

市值

$1.68B

市盈率 (TTM)

-41.4

17.8

股息率

52周最高

$14.39

52周最低

$4.24

52周范围

87%

排名62Top 92.6%

1.9

F-Score

改良版 Piotroski 分析

基于 9 年期基本面

疲弱 • 1.9 / 9 分

评分区间 (0-9)

8-9: 价值优异

6-7: 基本面强劲

4-5: 整体稳健

0-3: 表现疲弱

数据范围: 2017-2025

财务仪表盘

Q3 2025 数据

营业收入

$0.00+0.00%

近4季度走势

每股收益

-$0.08-38.46%

近4季度走势

自由现金流

-$10.89M+13.98%

近4季度走势

2025 Q3 财报亮点

核心亮点

Strong Financing Cash Inflow Net cash from financing activities totaled $120.7M, driven by June 2025 offering, boosting cash reserves to $56.9M.

Positive Phase 2b Trial Results CORAL trial met primary endpoint; 108 mg BID dose showed 60.2% reduction in 24-hour cough frequency versus placebo.

Net Loss Narrows Significantly Nine months net loss reduced to $34.4M from $36.5M, reflecting lower R&D spending compared to the prior year period.

Extended Cash Runway Forecast Total cash and marketable securities reached $193.9M, expected to fund operations and capital needs into fiscal year 2028.

关注风险

Need Substantial Future Funding Substantial expenditures expected for Phase 3 trials; failure to raise capital timely could delay or force abandonment of development.

Increased Operating Cash Burn Operating activities used $34.5M cash in nine months, up from $28.7M last year, increasing cash burn rate significantly.

Sole Product Candidate Dependency Business success relies entirely on Haduvio development, regulatory approval, and commercialization across IPF, non-IPF ILD, and RCC.

Opioid Class Label Warning Risk Active ingredient carries opioid class warning; potential for restrictive marketing or distribution regulations if applied to Haduvio.

前瞻展望

Key FDA Meeting Scheduled Planning End-of-Phase 2 meeting with FDA in Q4 2025; Phase 3 initiation for IPF expected in the first half of 2026.

Advance Multiple Clinical Programs Plan to initiate Phase 3 IPF trial and Phase 2b RCC trial in 2026, alongside ongoing TIDAL respiratory function study.

R&D Expenses Decreasing Nine month R&D expenses fell to $27.3M from $30.0M due to completion of several active Phase 2 clinical trials.

G&A Costs Increasing General and administrative expenses rose $2.6M for nine months, driven by personnel costs and SOX 404(b) compliance preparation.

同行对比

营业收入 (TTM)

NVAX

$1.12B

+64.7%

ARDX

$407.32M

+22.1%

SNDX

$172.35M

+627.8%

毛利率 (最新季度)

SNDX

102.3%

-13.9pp

NBTX

100.0%

+0.0pp

IMTX

100.0%

+0.0pp

关键指标

股票代码	市值	市盈率 (TTM)	净资产收益率 (TTM)	负债率
TERN	$3.78B	-40.8	-30.0%	0.3%
WVE	$2.45B	-11.6	-85.0%	2.8%
SYRE	$2.45B	-90.5	-29.4%	0.0%

长期趋势

近4季度

营业收入

净利润

经营现金流

4季度营收复合增长率

N/M

营收波动较大

4季度净利润复合增长率

N/M

盈利状态转变

现金流稳定性

现金流需要关注

深度研究

下次财报:2026年3月17日

每股收益:-$0.10

营业收入:-

财务数据

电话会议

财务报告

新闻

利润表

资产负债表

现金流量表

财务比率

变化率

利润表	过去12个月

无数据